Cholesterol Drug Pelacarsen Fails to Curb Heart Attacks
By @sharedot · · 8 pages
- Health
- Cardiology
- Pelacarsen
- Lipoprotein A
- Clinical Trials
Novartis's pelacarsen cut lipoprotein(a) by 78% in a major trial but failed to reduce heart attacks, strokes or cardiovascular deaths.
A 'slam dunk' trial comes up empty
An experimental Novartis injection called pelacarsen, long expected to become a major weapon against heart disease, showed no measurable impact on heart attack, stroke, cardiovascular death or procedures to restore blood flow, results presented Saturday at the American Heart Association meeting revealed.
"I really thought that this was going to be a slam dunk," said Dr. Amanda Doran of Vanderbilt University Medical Center, one of nearly 800 sites in the trial, per NBC News. Cleveland Clinic's Dr. Steven Nissen, who led the study, told NPR he was shocked: "I had high hopes for success."
Why the failure stunned cardiologists
The result is a consensus-breaking reversal. Lp(a) is an entirely genetic cholesterol particle that builds artery plaque and promotes clotting, untouched by diet or exercise, and roughly one in five people carry elevated levels.
NBC News reports the findings were also published Saturday in the New England Journal of Medicine, and Nissen said he had not expected that substantially lowering Lp(a) would fail to reduce major cardiovascular events.
Yale cardiologist Harlan Krumholz told NPR the outcome was "really jarring" given how high expectations had run.
Inside the Horizon trial
The Horizon trial enrolled people with high Lp(a) who had already suffered a heart attack, stroke or other cardiac problem. NBC News puts enrollment at 8,322 participants with an average age of 60 followed about five years; NPR reports 8,350 adults.
The drug cut Lp(a) by 78% versus 13% for placebo — a dramatic biochemical win that translated into zero clinical benefit. Novartis, which sponsored the study, said in a statement to NPR that it "provides meaningful evidence" about the Lp(a)-heart disease relationship.
Theories on what went wrong
Experts offered competing explanations, none confirmed. UCLA's Dr. Karol Watson suggested treatment may have come too late in life, since Lp(a) is high from conception; participants were also already aggressively treated for LDL and blood pressure, possibly shrinking residual risk, per NBC News.
NPR reports that Johns Hopkins' Roger Blumenthal said patients may need earlier or longer treatment, and Stanford's David Maron noted entry criteria may have required higher Lp(a) levels. Some now question whether Lp(a) causes events or merely marks risk.
Testing for Lp(a) still matters
Despite the disappointment, specialists urged people not to abandon Lp(a) screening, which new American College of Cardiology and American Heart Association guidelines say every adult should have measured once, since levels are fixed for life.
Cardiovascular disease remains the leading killer, responsible for more than 900,000 American deaths each year, NPR reports.
What comes next for Lp(a) drugs
No further study of pelacarsen is planned, Nissen said, but the pipeline remains crowded: Eli Lilly's lepodisiran, Amgen's olpasiran and Silence Therapeutics' zerlasiran all use siRNA approaches that may carry fewer injection-site side effects, with results over the next few years, per NPR.
Lilly is also testing an oral drug, muvalaplin, and CRISPR gene-editing designed to permanently switch off the Lp(a) gene is in early development, NBC News reports. "The take-home message is the story's not over," Watson told NPR.